Cocrystal Pharma (NASDAQ:COCP) Director Phillip Md Et Al Frost Buys 40,000 Shares

Cocrystal Pharma, Inc. (NASDAQ:COCP) Director Phillip Md Et Al Frost bought 40,000 shares of the business’s stock in a transaction on Friday, December 26th. The stock was bought at an average cost of $0.97 per share, for a total transaction of $38,800.00. Following the purchase, the director directly owned 1,768,551 shares of the company’s stock, valued at approximately $1,715,494.47. This trade represents a 2.31% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, December 24th, Phillip Md Et Al Frost bought 25,000 shares of Cocrystal Pharma stock. The shares were bought at an average price of $0.97 per share, with a total value of $24,250.00.
• On Wednesday, November 26th, Phillip Md Et Al Frost purchased 4,000 shares of Cocrystal Pharma stock. The stock was bought at an average cost of $0.99 per share, with a total value of $3,960.00.
• On Tuesday, November 25th, Phillip Md Et Al Frost purchased 20,000 shares of Cocrystal Pharma stock. The stock was purchased at an average price of $0.94 per share, for a total transaction of $18,800.00.

Cocrystal Pharma Stock Up 2.5%

Cocrystal Pharma stock traded up $0.02 during midday trading on Monday, hitting $1.00. 62,528 shares of the stock were exchanged, compared to its average volume of 426,375. The stock has a market capitalization of $13.74 million, a PE ratio of -1.06 and a beta of 1.04. The company has a fifty day simple moving average of $1.03 and a two-hundred day simple moving average of $1.33. Cocrystal Pharma, Inc. has a 52 week low of $0.90 and a 52 week high of $3.26.

Cocrystal Pharma (NASDAQ:COCP) last issued its earnings results on Friday, November 14th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.03. As a group, equities research analysts anticipate that Cocrystal Pharma, Inc. will post -1.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cocrystal Pharma in a report on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Cocrystal Pharma currently has a consensus rating of “Hold” and a consensus price target of $6.00.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.